News
The company is preparing a Phase 3 trial of enobosarm with a novel formulation that could extend its patent life.
Commissioner Martin Makary and two of his deputies aim to meet with drugmaker CEOs to discuss how the agency can “modernize” ...
The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...
The FDA has placed a clinical hold on the study while Rocket works with trial monitors and experts to investigate the cause ...
The agency recommends manufacturers update their vaccines to target the JN.1 strain. At the same time, HHS head Robert F.
The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.
The startup is the latest beneficiary of investors’ appetite for protein-degrading technology, which offers a way to reach ...
The advisory committee, which met after the agency rolled out new vaccine guidelines, said companies should tailor their ...
Still, the therapies’ modest benefit as a maintenance therapy points to how better treatments are needed for small cell lung ...
Already a Vigil Neuroscience investor, Sanofi has agreed to buy the rest of the biotech’s shares for $8 apiece, representing ...
The announcement, which followed the FDA setting new guidelines on COVID vaccine approvals, erased the stock’s gains from ...
The biotech, which has for years invested in genetics research, plans to acquire "substantially all" of testing firm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results